US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

Biotech Co. Inflated Gene Therapy Prospects, Investors Claim

By Rui Johnson Petri · March 29, 2024, 12:52 PM EDT

Massachusetts-based biotechnology company Bluebird Bio Inc. misled investors by understating the safety concerns of a gene therapy for sickle cell, causing damages when stock prices dropped, according to a proposed class...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Gill v. bluebird bio, Inc. et al

Case Number

1:24-cv-10803

Court

Massachusetts

Nature of Suit

Securities/Commodities

Date Filed

March 28, 2024

Featured Stories

Biggest Rulings For Patent Attys In 2026: A Midyear Report No Photo Available

Dani Kass

The U.S. Supreme Court clarified the pleading standard for induced infringement of skinny labels, and the Federal Circuit opened the d... (more story)

AI Notetakers For Doctors Raise 'Bycatching' Liability Risks No Photo Available

Mark Payne

Busy doctors have embraced AI-powered devices that record patient conversations and generate visit notes. The expansion of ambient not... (more story)

Healthcare Deals This Week: AstraZeneca, Novartis, Vertex No Photo Available

Yeji Jesse Lee

Despite a short week, healthcare dealmakers were busy at work, as Law360 counted at least four billion-dollar transactions involving n... (more story)